News

Rapid MDx on infections
Enlarge image

BusinessUKFinlandFranceIreland

Rapid MDx on infections

03.09.2012 - EU-funded researchers will use a €6m grant to develop cost-effective molecular diagnostics (MDx) tools for the rapid diagnosis of infections.

The aim is to come up with a test that would reduce the diagnosis time of respiratory tract infections from days to hours, so that the appropriate treatments can be administered as early as possible, giving patients the best possible chance of a swift recovery. These diagnostic products will be based on a novel "sample-in, result-out" technology platform.
The project, titled RID-RTI ('Rapid Identification of Respiratory Tract Infections'), brings together researchers from small and medium-sized enterprises (SMEs), universities and hospitals. The Molecular Diagnostics Research Group at the National University of Ireland, Galway; French diagnostics firm Genewave;  Finnish biotech company Mobidiag; Assistance Publique Hopitaux de Paris; and University College London are part of the consortium. They receive a €6m boost of funding from the EU's Seventh Framework Programme (FP7).
Respiratory tract infections, such as pneumonia, are amongst the top four major causes of morbidity and mortality worldwide. „Speed and accuracy are key to appropriate therapy and survival of the patient. The ultimate objective is to develop new cost effective, user-friendly products that will be routinely used in hospitals“, stated Thomas Barry from the Molecular Diagnostics Research Group at NUI Galway in Ireland. „This could replace time-consuming and labour-intensive methods so that a diagnosis can be achieved within a couple of hours, rather than days or weeks.“

http://www.european-biotechnology-news.com/news/news/2012-03/rapid-mdx-on-infections.html

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.40 EUR11.63%
  • SARTORIUS113.95 EUR4.93%
  • EVONIK27.85 EUR3.69%

FLOP

  • ADDEX3.30 CHF-4.07%
  • BIOFRONTERA1.95 EUR-3.47%
  • MEDIGENE3.70 EUR-2.63%

TOP

  • CYTOS0.33 CHF43.5%
  • ADDEX3.30 CHF42.2%
  • FORMYCON14.30 EUR41.9%

FLOP

  • BIOFRONTERA1.95 EUR-15.2%
  • ACTELION100.20 CHF-13.8%
  • MOLOGEN5.60 EUR-11.8%

TOP

  • SANTHERA105.50 CHF2570.9%
  • WILEX1.96 EUR168.5%
  • BB BIOTECH256.75 EUR98.6%

FLOP

  • CYTOS0.33 CHF-90.9%
  • MOLOGEN5.60 EUR-51.0%
  • 4SC0.82 EUR-50.9%

No liability assumed, Date: 29.01.2015